Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Castle Biosciences Inc (CSTL) USD0.001

Sell:$43.88 Buy:$49.60 Change: $0.87 (2.00%)
Market closed |  Prices as at close on 27 November 2020 | Switch to live prices |
Change: $0.87 (2.00%)
Market closed |  Prices as at close on 27 November 2020 | Switch to live prices |
Change: $0.87 (2.00%)
Market closed |  Prices as at close on 27 November 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company has two market proprietary products, DecisionDx-Melanoma and DecisionDx-UM, and have two active proprietary products in development DecisionDx-UM and DecisionDx-Melanoma. The Company is developing a treatment plan for certain cancers using clinical and pathology factors. Its lead product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP), a test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer.

Contact details

820 S Friendswood Dr Ste 201
United States
+1 (281) 7969032

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$868.13 million
Shares in issue:
19.91 million
Health Care Services
United States
US dollar

Key personnel

  • Daniel Bradbury
    Independent Chairman of the Board
  • Derek Maetzold
    President, Chief Executive Officer, Founder, Director
  • Frank Stokes
    Chief Financial Officer
  • Toby Juvenal
    Senior Vice President - Sales
  • Kristen Oelschlager
    Senior Vice President - Clinical Operations
  • Alice Izzo
    Vice President - Marketing
  • Bob Cook
    Vice President - Research & Development
  • Michael Maltby
    Executive Director - Managed Care
  • Noreen Manning
    Executive Director - Reimbursement
  • Bernhard Spiess
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.